- Home
- RFM vs GUTS Comparison
RFM vs GUTS Comparison
Compare RFM & GUTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RFM
- GUTS
- Stock Information
- Founded
- RFM 2020
- GUTS 2010
- Country
- RFM United States
- GUTS United States
- Employees
- RFM N/A
- GUTS N/A
- Industry
- RFM Finance/Investors Services
- GUTS
- Sector
- RFM Finance
- GUTS
- Exchange
- RFM Nasdaq
- GUTS NYSE
- Market Cap
- RFM 92.3M
- GUTS 110.1M
- IPO Year
- RFM N/A
- GUTS 2024
- Fundamental
- Price
- RFM $15.35
- GUTS $1.82
- Analyst Decision
- RFM
- GUTS Buy
- Analyst Count
- RFM 0
- GUTS 2
- Target Price
- RFM N/A
- GUTS $18.00
- AVG Volume (30 Days)
- RFM 20.7K
- GUTS 373.0K
- Earning Date
- RFM 01-01-0001
- GUTS 02-02-2025
- Dividend Yield
- RFM 9.74%
- GUTS N/A
- EPS Growth
- RFM N/A
- GUTS N/A
- EPS
- RFM N/A
- GUTS N/A
- Revenue
- RFM N/A
- GUTS $97,000.00
- Revenue This Year
- RFM N/A
- GUTS N/A
- Revenue Next Year
- RFM N/A
- GUTS N/A
- P/E Ratio
- RFM N/A
- GUTS N/A
- Revenue Growth
- RFM N/A
- GUTS N/A
- 52 Week Low
- RFM $12.89
- GUTS $1.74
- 52 Week High
- RFM $16.41
- GUTS $14.50
- Technical
- Relative Strength Index (RSI)
- RFM 53.96
- GUTS 41.31
- Support Level
- RFM $14.95
- GUTS $1.77
- Resistance Level
- RFM $15.21
- GUTS $2.10
- Average True Range (ATR)
- RFM 0.12
- GUTS 0.16
- MACD
- RFM 0.06
- GUTS -0.01
- Stochastic Oscillator
- RFM 100.00
- GUTS 9.18
About RFM RiverNorth Flexible Municipal Income Fund Inc.
RiverNorth Flexible Municipal Income Fund Inc is a diversified, closed-end management investment company. Its primary investment objective is to seek current income exempt from regular U.S. federal income taxes. The fund's secondary investment objective is total return.
About GUTS FRACTYL HEALTH INC
Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.